Keyphrases
Diffuse Large B-cell Lymphoma (DLBCL)
50%
Hodgkin Lymphoma
28%
B-cell Lymphoma
27%
Lymphoma Cells
26%
Endoplasmic Reticulum Aminopeptidase
23%
18F-fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET)
23%
Mutational Evolution
23%
Prognostic Marker
23%
Tumor Necrosis
23%
MYC Rearrangement
23%
MiR-150
23%
Plasmacytoma Variant Translocation 1 (PVT1)
23%
ZDHHC11
23%
Promoting Role
23%
MicroRNA
23%
Immunoglobulin Heavy Chain
23%
Non-Hodgkin Lymphoma
23%
CRISPR Interference (CRISPRi)
23%
Necrosis
17%
Burkitt Lymphoma
15%
Overexpression
12%
CircPVT1
10%
Oncogene
10%
Diffuse Large B-cell Lymphoma Cells
10%
Survival Analysis
8%
Disease-specific Survival
8%
SUVmax
8%
Expression Pattern
7%
Translocated
7%
Enhancer RNA (eRNA)
7%
Network Components
6%
Expression Level
6%
Cell Growth
6%
Total Lesion Glycolysis
5%
Patient Survival
5%
FDG-PET Scan
5%
Genomic Models
5%
PET Parameters
5%
Adverse Prognostic Factor
5%
Tumor Volume
5%
Metabolic
5%
Enhancer Region
5%
Immunology and Microbiology
B Cell
100%
Lymphoma Cell
53%
Gene Expression Profiling
23%
Plasmacytoma
23%
Allele
23%
Aminopeptidase
23%
Human Leukocyte Antigen
23%
Binding Site
23%
Endoplasmic reticulum
23%
Antigen Presentation
23%
Enhancer Region
23%
Immunoglobulin Heavy Chain
23%
Clustered Regularly Interspaced Short Palindromic Repeat
23%
Cell Growth
19%
B Cell Lymphoma Cell
17%
Germinal Center
11%
Oncogene
7%
Immune Response
6%
Prednisolone
5%
Glycoprotein
5%
Cyclophosphamide
5%
Whole Exome Sequencing
5%
Gene Mutation
5%
Immunoprecipitation
5%
Rituximab
5%
Non-Hodgkin Lymphoma Cell Line
5%
B-Cell Receptor
5%
Biochemistry, Genetics and Molecular Biology
B Cell
77%
Long Non-Coding RNA
32%
Gene Expression Profiling
25%
Allele
23%
Myc
23%
Aminopeptidase
23%
Binding Site
23%
Human Leukocyte Antigen
23%
Antigen Presentation
23%
Cell Growth
13%
ERAP2
7%
Immune Response
6%
Glycoprotein
5%
Messenger RNA
5%
Tumor Suppressor Protein
5%
Exome Sequencing
5%
Prednisolone
5%
Tyrosine
5%
Rituximab
5%
PIM1
5%
Circular RNA
5%
Doxorubicin
5%
Cyclophosphamide
5%
Gene Mutation
5%
